NO20074512L - Anti-interferon alfa monoklonale antistoffer og anvendelsesmetoder - Google Patents

Anti-interferon alfa monoklonale antistoffer og anvendelsesmetoder

Info

Publication number
NO20074512L
NO20074512L NO20074512A NO20074512A NO20074512L NO 20074512 L NO20074512 L NO 20074512L NO 20074512 A NO20074512 A NO 20074512A NO 20074512 A NO20074512 A NO 20074512A NO 20074512 L NO20074512 L NO 20074512L
Authority
NO
Norway
Prior art keywords
ifnα
bioactivity
antibodies
subtypes
methods
Prior art date
Application number
NO20074512A
Other languages
English (en)
Other versions
NO343054B1 (no
Inventor
Jacques Banchereau
Kiley Prilliman
Virginia Pascual
Anna Karolina Palucka
Original Assignee
Baylor Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Res Inst filed Critical Baylor Res Inst
Publication of NO20074512L publication Critical patent/NO20074512L/no
Publication of NO343054B1 publication Critical patent/NO343054B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Sammendrag Foreliggende oppfinnelse inkluderer sammensetninger og fremgangsmåter som inkluderer antistoffer som selektivt nøytraliserer en bioaktivitet fra minst to interferon alfa ("IFNa") proteinsubtyper for proteinsubtypene A, 2, 132, C, F, G, 1-12, 1, JI, K, 4a, 4b og WA, men nøytraliserer ikke minst en bioaktivitet av IFNa-proteinsubtype D. Eksempler på bioaktivitet for måling inkluderer aktivering av MxA-promoteren eller antiviral aktivitet og varianter, derivater og fragmenter derav. Oppfinnelsen inkluderer også vertsceller, hybridomer og plasmacytomer som produserer antistoffer. På grunn av deres unike selektivitet og affinitet, er antistoffene av den foreliggende oppfinnelsen nyttige for ådetektere IFNa -subtyper i prøve eller vev og/eller for terapeutisk anvendelse som inkluderer, men ikke er begrenset til, behandlingen og/eller forbedringen av en IFNa-relatert forstyrrelse slik som SLE, lupus, type I diabetes, psoriasis, AIDS og Graft versus Vert sykdom.
NO20074512A 2005-02-10 2007-09-06 Anti-interferon  monoklonale antistoffer og anvendelser NO343054B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65223305P 2005-02-10 2005-02-10
PCT/US2006/004643 WO2006086586A2 (en) 2005-02-10 2006-02-09 Anti-interferon alpha monoclonal antibodies and methods for use

Publications (2)

Publication Number Publication Date
NO20074512L true NO20074512L (no) 2007-10-31
NO343054B1 NO343054B1 (no) 2018-10-22

Family

ID=36694481

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074512A NO343054B1 (no) 2005-02-10 2007-09-06 Anti-interferon  monoklonale antistoffer og anvendelser

Country Status (14)

Country Link
US (2) US8080638B2 (no)
EP (1) EP1851248B1 (no)
JP (2) JP5837730B2 (no)
KR (1) KR101363120B1 (no)
CN (1) CN101155831B (no)
AU (1) AU2006213800B2 (no)
BR (1) BRPI0607490A2 (no)
CA (1) CA2597265C (no)
IL (1) IL184808A0 (no)
MX (1) MX2007009466A (no)
NO (1) NO343054B1 (no)
RU (1) RU2431638C2 (no)
WO (1) WO2006086586A2 (no)
ZA (1) ZA200706425B (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0516470A (pt) * 2004-10-07 2008-09-09 Universitot Zuerich uso de um agente de bloqueio do interferon tipo i, e, método de prevenção e tratamento da psorìase
WO2006086586A2 (en) 2005-02-10 2006-08-17 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
US7888481B2 (en) 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
EP2057190A4 (en) * 2006-08-09 2010-07-28 Baylor Res Inst MONOCLONAL ANTI-INTERFERON ALPHA ANTIBODIES AND USE METHOD THEREFOR
EP2687232A1 (en) * 2006-12-06 2014-01-22 MedImmune, LLC Methods of treating systemic lupus erythematosus
EP2077858A4 (en) * 2006-12-06 2011-07-20 Medimmune Llc INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS
EP2118324B1 (en) * 2007-01-25 2012-06-13 Université Libre de Bruxelles Method for evaluating the response of an individual to a treatment with a type i interferon (ifn)
CA2682292A1 (en) * 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody
EP2076590A4 (en) * 2007-05-03 2011-06-01 Medimmune Llc SELF-IMMUNE DISEASE SELF-ANTIBODY MARKERS
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
WO2009108341A1 (en) 2008-02-28 2009-09-03 Argos Therapeutics, Inc. Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection
MX2010012052A (es) * 2008-05-07 2010-12-14 Novo Nordisk As Anticuerpos humanizados contra interferon-alfa humano.
MX2011001506A (es) * 2008-08-14 2011-03-15 Genentech Inc Metodos para eliminar un contaminante utilizado cromatografia de membrana de intercambio de ion en desplazamiento de proteina indigena.
CN101580546B (zh) * 2009-06-04 2011-09-14 中国疾病预防控制中心病毒病预防控制所 人源抗人干扰素α抗体及其应用
SG183542A1 (en) 2010-03-12 2012-10-30 Immunogen Inc Cd37-binding molecules and immunoconjugates thereof
EP2694105A4 (en) 2011-04-01 2015-04-29 Immunogen Inc CD37 BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF
AU2013204880B2 (en) * 2011-04-26 2016-11-24 Genentech, Inc. Compositions and method for treating autoimmune diseases
AU2012249601A1 (en) * 2011-04-26 2013-05-09 Genentech, Inc. Compositions and method for treating autoimmune diseases
US9902770B2 (en) 2013-03-15 2018-02-27 Janssen Biotech, Inc. Interferon alpha and omega antibody antagonists
CN112358548B (zh) 2013-07-03 2024-10-25 因美诺克股份公司 人抗IFN-α抗体、IFN-α结合片段、多核苷酸、组合物、试剂盒及应用和制备方法
AU2014365838B2 (en) * 2013-12-16 2021-01-14 The University Of North Carolina At Chapel Hill Depletion of plasmacytoid dendritic cells
CR20170383A (es) * 2015-01-23 2017-11-22 Sanofi Sa Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
SG10202108116SA (en) 2015-06-08 2021-08-30 Debiopharm International S A Anti-cd37 immunoconjugate and anti-cd20 antibody combinations
US11104740B2 (en) 2015-08-28 2021-08-31 Debiopharm International, S.A. Antibodies and assays for detection of CD37
RU2756109C2 (ru) * 2016-03-10 2021-09-28 Виела Байо, Инк. Связывающие ilt7 молекулы и способы их применения
US11278629B2 (en) 2016-11-02 2022-03-22 Debiopharm International, S.A. Methods for improving anti-CD37 immunoconjugate therapy
CN107858449A (zh) * 2017-12-05 2018-03-30 安徽九川生物科技有限公司 一种犬干扰素α生物学活性检测方法
JP7506601B2 (ja) 2017-12-06 2024-06-26 アビディティー バイオサイエンシーズ，インク． 筋萎縮症と筋緊張性ジストロフィーを処置するための組成物および方法
RU2694672C1 (ru) * 2018-04-27 2019-07-16 Открытое акционерное общество "Всероссийский научный Центр молекулярной диагностики и лечения" (ОАО ВНЦМДЛ) Вариабельные домены лёгкой и тяжёлой цепи мышиного моноклонального антитела против интерферона альфа (IFN-α) человека, антигенсвязывающий фрагмент (Fab) против IFN-α человека, содержащий указанные домены
US12144818B2 (en) 2018-05-30 2024-11-19 Debiopharm International, S.A. Method for treating cancer in a human patient by administering an anti-CD37 immunoconjugate using various dosing regimens
JP2022527542A (ja) 2019-04-04 2022-06-02 ヤンセン バイオテツク，インコーポレーテツド 抗ＩＦＮ－α／ω抗体の投与方法
RU2737466C1 (ru) * 2019-12-30 2020-11-30 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Гуманизированное нейтрализующее антитело к интерферону-бета человека
RU2748953C1 (ru) * 2019-12-30 2021-06-02 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Рекомбинантный Fab-scFv на основе нейтрализующего антитела против интерферона бета-1а человека и антитела против рецептора ErbB2 человека
AU2021241682B2 (en) * 2020-03-27 2026-02-12 Avidity Biosciences, Inc. Compositions and methods of treating muscle dystrophy
CN119841955A (zh) * 2023-12-19 2025-04-18 重庆艾生斯生物工程有限公司 一种抗MxA抗体或其功能性片段及其应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3001687C2 (de) 1980-01-18 1981-09-17 Kläger, Karlheinz, 8901 Neusäß Verstellbare Düse an einem handbetätigten Flüssigkeitszerstäuber
US4423147A (en) * 1980-04-11 1983-12-27 Secher David S Monoclonal antibody to interferon-α
US4824432A (en) * 1981-03-24 1989-04-25 S.V.S. Laboratories, Inc. Method for treating AIDS and other immune deficiencies and immune disorders
US4362155A (en) * 1981-03-24 1982-12-07 Skurkovich Simon V Method and apparatus for the treatment of autoimmune and allergic diseases
US4605394A (en) * 1982-12-03 1986-08-12 Simon V. Skurkovich Methods for the treatment of pathological conditions by removing interferon from the organism
DE3211263A1 (de) * 1981-03-31 1983-01-27 Otsuka Pharmaceutical Co. Ltd., Tokyo Human-interferon verwandte peptide, antigene und antikoerper, sowie verfahren zu deren herstellung
EP0139676B1 (en) * 1983-02-04 1992-11-25 Cytoclonal Pharmaceutics Inc. Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
FR2560212B1 (fr) * 1984-02-24 1989-12-29 Unicet Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
AU2844889A (en) 1988-01-22 1989-07-27 Collagen Corporation Method for suppressing the growth of normal and cancer cells
US5889151A (en) * 1989-10-20 1999-03-30 Societe Leb-Tech Purified human alpha interferon receptor
AU653937B2 (en) * 1991-04-17 1994-10-20 Medisup International N.V. Water-soluble polypeptides having high affinity for interferons alpha and beta
JPH06510061A (ja) 1991-08-30 1994-11-10 ジェネンテク，インコーポレイテッド Ｉｄｄｍの治療法
DE69324671D1 (de) * 1992-02-10 1999-06-02 Interferon Sciences Inc Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute
EP0563487A1 (en) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
US5821078A (en) * 1992-09-03 1998-10-13 Yeda Research And Development Co. Ltd. Nucleic acid encoding interferon-α/β binding protein
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5780027A (en) * 1995-07-14 1998-07-14 Meiogen Biotechnology Corporation Methods of treatment of down syndrome by interferon antagonists
IL118096A0 (en) * 1996-05-01 1996-09-12 Yeda Res & Dev Antibodies against interferon alpha/beta receptor
US6713609B1 (en) * 1996-07-16 2004-03-30 Genentech, Inc. Monoclonal antibodies to type I interferon receptor
AU4070897A (en) 1996-08-16 1998-03-06 Kurt B. Osther Method for treating diabetes
US5804955A (en) * 1996-10-30 1998-09-08 Cherry Semiconductor Corporation Low voltage current limit circuit with temperature insensitive foldback network
US20030018174A1 (en) * 1997-10-06 2003-01-23 Genentech, Inc. Monoclonal antibodies to IFNAR2
US6331396B1 (en) 1998-09-23 2001-12-18 The Cleveland Clinic Foundation Arrays for identifying agents which mimic or inhibit the activity of interferons
AUPP670698A0 (en) 1998-10-23 1998-11-19 Monash University A method of regulation
KR20000034847A (ko) * 1998-11-17 2000-06-26 성재갑 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
AU785198B2 (en) 1999-11-15 2006-11-02 Miltenyi Biotec B.V. & Co. KG Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognised thereby and cells obtained thereby
GB0001710D0 (en) 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic treatment
GB0001712D0 (en) * 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic peptides
US6846486B1 (en) * 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
WO2002024874A2 (en) * 2000-09-21 2002-03-28 Schering Corporation Methods for preparing interferon producing dentitric cells
BR0206364A (pt) * 2001-01-09 2005-08-16 Baylor Res Inst Métodos para tratar doenças auto-imunes em um indivìduo e testes diagnósticos in vitro
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
FR2822845B1 (fr) * 2001-03-30 2003-12-12 Genodyssee Nouveaux polynucleotides comportant des polymorphismes de type snp fonctionnels dans la sequence nucleotidique du gene ifn-alpha-21 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
EP1474432A1 (en) 2002-02-04 2004-11-10 Biomira Inc. Immunostimulatory, covalently lipidated oligonucleotides
AU2002368062A1 (en) 2002-06-26 2004-01-19 Imclone Systems Incorporated Bispecific antibodies that bind to vegf receptors
US7438907B2 (en) * 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25
KR100872210B1 (ko) 2003-04-23 2008-12-05 메다렉스, 인코포레이티드 인터페론 알파 수용체-1 (ｉｆｎａｒ-1)에 대한 인체화항체
NZ547157A (en) * 2003-12-10 2009-07-31 Medarex Inc Interferon Alpha Antibodies and their uses
BRPI0516470A (pt) * 2004-10-07 2008-09-09 Universitot Zuerich uso de um agente de bloqueio do interferon tipo i, e, método de prevenção e tratamento da psorìase
US7888481B2 (en) 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
WO2006086586A2 (en) 2005-02-10 2006-08-17 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
EP2057190A4 (en) 2006-08-09 2010-07-28 Baylor Res Inst MONOCLONAL ANTI-INTERFERON ALPHA ANTIBODIES AND USE METHOD THEREFOR
MX2010012052A (es) 2008-05-07 2010-12-14 Novo Nordisk As Anticuerpos humanizados contra interferon-alfa humano.

Also Published As

Publication number Publication date
NO343054B1 (no) 2018-10-22
JP5837730B2 (ja) 2015-12-24
CN101155831A (zh) 2008-04-02
JP2014111644A (ja) 2014-06-19
WO2006086586A2 (en) 2006-08-17
IL184808A0 (en) 2007-12-03
RU2431638C2 (ru) 2011-10-20
US20120020963A1 (en) 2012-01-26
CA2597265A1 (en) 2006-08-17
ZA200706425B (en) 2014-07-30
US8333965B2 (en) 2012-12-18
MX2007009466A (es) 2007-12-07
KR20070107753A (ko) 2007-11-07
BRPI0607490A2 (pt) 2009-09-08
US20080160030A1 (en) 2008-07-03
US8080638B2 (en) 2011-12-20
EP1851248B1 (en) 2016-08-10
EP1851248A2 (en) 2007-11-07
JP2008529529A (ja) 2008-08-07
CA2597265C (en) 2015-03-24
WO2006086586A3 (en) 2006-10-12
AU2006213800B2 (en) 2012-02-09
KR101363120B1 (ko) 2014-02-13
RU2007133608A (ru) 2009-03-20
AU2006213800A1 (en) 2006-08-17
CN101155831B (zh) 2015-08-19

Similar Documents

Publication Publication Date Title
NO20074512L (no) Anti-interferon alfa monoklonale antistoffer og anvendelsesmetoder
WO2008021976A3 (en) Anti-interferon alpha monoclonal antibodies and methods for use
ES2623805T3 (es) Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de fenilalanil-alfa-ARNt sintetasas
Gillich et al. Effect of variants in LGP2 on MDA5-mediated activation of interferon response and suppression of hepatitis D virus replication
DE602005027258D1 (de) Humane monoklonale antikörper gegen hendra- und nipah-viren
RU2014122609A (ru) Модифицированная константная область антитела
KR20230015365A (ko) Ace2 융합 단백질 및 이의 용도
NO20052071L (no) Bezofuranforbindelser, preparater og metoder for behandling og forebygging av hepatitt C virale infeksjoner og relaterte sykdommer.
NO20081654L (no) Stabiliserte GLP-1-analoger
WO2005016132A3 (en) Diagnostics for sars virus
Li et al. Programmed− 2/− 1 ribosomal frameshifting in simarteriviruses: an evolutionarily conserved mechanism
Dreymueller et al. Smooth muscle cells relay acute pulmonary inflammation via distinct ADAM17/ErbB axes
KR20230093483A (ko) Ace2 융합 단백질 및 이의 용도
Jiang et al. Serum soluble ST2 is a promising prognostic biomarker in HBV-related acute-on-chronic liver failure
PE20050197A1 (es) Anticuerpos de virus anti-dengue, composiciones, metodos y usos
SA03230564A (ar) محفزات مستقبل عامل اطلاق الكورتيكوتروبين -2
Guo et al. Attachment, entry, and intracellular trafficking of classical swine fever virus
WO2005051318A3 (en) Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
Wang Interleukin‑18 binding protein: Biological properties and roles in human and animal immune regulation
Gruber et al. Differential signaling of cmvIL‐10 through common variants of the IL‐10 receptor 1
Fan et al. Molecular characterization of the type I IFN receptor in two woodchuck species and detection of its expression in liver samples from woodchucks infected with woodchuck hepatitis virus (WHV)
WO2005002501A3 (en) Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same
JP2007520461A (ja) 肝炎ウイルスの負荷を変えるための方法および化合物
NO20060675L (no) Forbedrede, rekombinante, humane interferon-beta-lb-polypeptider
ITRM20010336A1 (it) Anticorpo umano ricombinante diretto contro la proteina non strutturale ns3 del virus dell'epatite c (hcv), acido nucleico codificante e usi